Ligand Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +22.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 12.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 115.2x | Better than 3% |
| Forward P/E | 69.0x | Better than 5% |
| Price / Sales | 24.3x | Better than 5% |
| P/E vs own 5-yr range | 99th pctl | Better than 3% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 11.0% | Better than 67% |
| Net income CAGR (3Y) | -26.4% | Better than 13% |
| Free cash flow CAGR (3Y) | -31.8% | Better than 10% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 94.6% | Better than 98% |
| Operating margin | 17.6% | Better than 71% |
| Net margin | 46.4% | Better than 97% |
| Return on equity | 13.5% | Better than 64% |
| Return on invested capital | 10.2% | Better than 68% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 0.2% | Better than 74% |
| 6-month return | 25.1% | Better than 87% |
| 12-month return (ex latest month) | 52.4% | Better than 84% |
| Distance below 52-week high | 12.2% | Better than 78% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 22.2x | Better than 98% |
| Debt to assets | 28.9% | Better than 43% |
| Interest coverage | 34.7x | Better than 88% |
| Free cash flow / net income | 30.6% | Better than 8% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 27.9% | Better than 46% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 286.94
- Open
- 285.21
- Day range
- 282.36 - 291.36
- Avg price
- 287.26
- Volume
- 259.79K
- Turnover
- 74.63M
- Turnover ratei
- 1.33%
- Volume ratioi
- 1.11
- Amplitudei
- 3.14%
- 52-week rangei
- 175.89 - 326.63
Valuation
- P/Ei
- 46.79
- P/E (TTM)i
- 115.20
- P/Bi
- 5.97
- EPSi
- 6.13
- Book value / shi
- 48.08
- Net profit
- 122.62M
- Net assets
- 961.76M
Share structure
- Market cap
- 5.74B
- Float capi
- 5.61B
- Shares out
- 20.00M
- Float sharesi
- 19.56M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
12.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+10.08M net over the window
Short interest
- Shares short
- 2.46M
- % of floati
- 12.36%
- Days to coveri
- 10.53
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ligand Pharmaceuticals (LGND)?
Ligand Pharmaceuticals last traded at 286.85. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ligand Pharmaceuticals's market cap?
About 5.74B.
What is the P/E ratio of Ligand Pharmaceuticals?
The trailing twelve-month P/E is 115.20. The Valuation tab shows it against the stock's own five-year range.
Does Ligand Pharmaceuticals pay a dividend?
Ligand Pharmaceuticals does not currently pay a regular dividend.
Is Ligand Pharmaceuticals a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 367.00, which implies 27.9% upside from the current price. This is not investment advice.
What is Ligand Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ligand Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ligand Pharmaceuticals discussion 0 comments